Clinical Trials
2 trialsNCT03835819 2026-06-01
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03832361 2025-07-18
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
Yale University
Phase 2 Recruiting